Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Rating of “Hold” by Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have earned a consensus rating of “Hold” from the twelve ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $13.1429.

A number of equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Tuesday, April 21st. TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Royal Bank Of Canada set a $3.00 price target on Jasper Therapeutics and gave the stock a “sector perform” rating in a research note on Friday, May 15th. Finally, UBS Group assumed coverage on Jasper Therapeutics in a report on Monday, March 23rd. They set a “neutral” rating on the stock.

Institutional Investors Weigh In On Jasper Therapeutics

Large investors have recently made changes to their positions in the company. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics in the 4th quarter worth approximately $26,000. Panagora Asset Management Inc. acquired a new stake in Jasper Therapeutics during the 4th quarter valued at $35,000. Acadian Asset Management LLC acquired a new stake in Jasper Therapeutics during the 1st quarter valued at $46,000. Voleon Capital Management LP purchased a new stake in shares of Jasper Therapeutics in the third quarter valued at $50,000. Finally, Jain Global LLC purchased a new stake in shares of Jasper Therapeutics in the fourth quarter valued at $79,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $0.47 on Wednesday. The firm has a market cap of $13.05 million, a price-to-earnings ratio of -0.14 and a beta of 3.00. Jasper Therapeutics has a 1 year low of $0.42 and a 1 year high of $7.19. The firm’s 50 day moving average price is $0.83 and its two-hundred day moving average price is $1.28.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08. As a group, equities analysts predict that Jasper Therapeutics will post -1.81 EPS for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.